Who are Lutein/zeaxanthin and DHA/EPA's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): lipoic acid and omega-3 fatty acids, L-arginine and liposomal vitamin C, DHA plus Vitamin D.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lutein-zeaxanthin-and-dha-epa.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Lutein/zeaxanthin and DHA/EPA — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lutein/zeaxanthin and DHA/EPA (Lutein/zeaxanthin and DHA/EPA) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nutritional supplement combination. Area: Ophthalmology.

phase 3 Nutritional supplement combination Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Lutein/zeaxanthin and DHA/EPA (Lutein/zeaxanthin and DHA/EPA) — National Eye Institute (NEI). Lutein, zeaxanthin, and omega-3 fatty acids (DHA/EPA) accumulate in the retina to protect against oxidative damage and support macular health.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Lutein/zeaxanthin and DHA/EPA TARGET	Lutein/zeaxanthin and DHA/EPA	National Eye Institute (NEI)	phase 3	Nutritional supplement combination
lipoic acid and omega-3 fatty acids	lipoic acid and omega-3 fatty acids	Oregon Health and Science University	marketed	Nutritional supplement combination
L-arginine and liposomal vitamin C	L-arginine and liposomal vitamin C	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	phase 3	Nutritional supplement combination
DHA plus Vitamin D	DHA plus Vitamin D	Bambino Gesù Hospital and Research Institute	phase 3	Nutritional supplement combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nutritional supplement combination class)

Bambino Gesù Hospital and Research Institute · 1 drug in this class
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · 1 drug in this class
National Eye Institute (NEI) · 1 drug in this class
Oregon Health and Science University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lutein/zeaxanthin and DHA/EPA — Competitive Intelligence Brief. https://druglandscape.com/ci/lutein-zeaxanthin-and-dha-epa. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab